| Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II (NCT06882499) | Peter MacCallum Cancer Centre, Australia | 2026-06-01 |
| Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary (NCT07434180) | Peter MacCallum Cancer Centre, Australia | 2026-06-01 |
| Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease (NCT07541391) | Peter MacCallum Cancer Centre, Australia | 2026-05-01 |
| Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC) (NCT07527819) | Peter MacCallum Cancer Centre, Australia | 2026-04-08 |
| Novel Treatment of Radiation Associated Dysphagia With Statins (NCT07217938) | Peter MacCallum Cancer Centre, Australia | 2025-12-05 |
| Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever (NCT07051525) | Peter MacCallum Cancer Centre, Australia | 2025-12-03 |
| A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment (NCT07387978) | Peter MacCallum Cancer Centre, Australia | 2025-11-26 |
| EQUIP - Evaluation of Quality of Imaging on a Next-generation Total Body Pet Scan in Comparison to Conventional PET (NCT07263815) | Peter MacCallum Cancer Centre, Australia | 2025-11-24 |
| Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (NCT07090369) | Peter MacCallum Cancer Centre, Australia | 2025-11-01 |
| IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma (NCT07138222) | Peter MacCallum Cancer Centre, Australia | 2025-09-11 |
| Home-Based Photo-Biomodulation for Management of Lymphoedema and Radiation Fibrosis in Patients After Head and Neck Cancer: A Single-Arm Feasibility Trial (NCT07139782) | Peter MacCallum Cancer Centre, Australia | 2025-09-04 |
| Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib (NCT06812715) | Peter MacCallum Cancer Centre, Australia | 2025-05-05 |
| MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (NCT06414148) | Peter MacCallum Cancer Centre, Australia | 2024-05-14 |
| Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy (NCT05560659) | Peter MacCallum Cancer Centre, Australia | 2023-12-14 |
| CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (NCT05666700) | Peter MacCallum Cancer Centre, Australia | 2023-12-08 |
| Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions (NCT06105411) | Peter MacCallum Cancer Centre, Australia | 2023-12-01 |
| Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma (NCT05864742) | Peter MacCallum Cancer Centre, Australia | 2023-09-07 |
| Metabolic Phenotypes in Melanoma (NCT05570227) | Peter MacCallum Cancer Centre, Australia | 2023-06-27 |
| Deep sequencIng in Cutaneous Squamous CEll caRciNomas (NCT05878288) | Peter MacCallum Cancer Centre, Australia | 2023-05-26 |
| Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer (NCT05425862) | Peter MacCallum Cancer Centre, Australia | 2022-10-21 |
| EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T (NCT05521412) | Peter MacCallum Cancer Centre, Australia | 2022-09-29 |
| Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer (NCT05383079) | Peter MacCallum Cancer Centre, Australia | 2022-09-13 |
| Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (NCT05340374) | Peter MacCallum Cancer Centre, Australia | 2022-07-14 |
| Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study) (NCT05196789) | Peter MacCallum Cancer Centre, Australia | 2022-03-18 |
| PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI (NCT05154162) | Peter MacCallum Cancer Centre, Australia | 2022-03-02 |
| A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (NCT04985721) | Peter MacCallum Cancer Centre, Australia | 2022-02-24 |
| FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary (NCT05263700) | Peter MacCallum Cancer Centre, Australia | 2022-02-23 |
| NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NCT05024318) | Peter MacCallum Cancer Centre, Australia | 2022-02-08 |
| Invasive Fungal Infections in Patients Following Stem Cell Transplant (NCT04619147) | Peter MacCallum Cancer Centre, Australia | 2022-01-15 |
| PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study (NCT05222087) | Peter MacCallum Cancer Centre, Australia | 2022-01-03 |
| PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (NCT05053854) | Peter MacCallum Cancer Centre, Australia | 2021-12-08 |
| Perioperative Pharmacogenomic Testing (NCT05063838) | Peter MacCallum Cancer Centre, Australia | 2021-11-29 |
| Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (NCT04801966) | Peter MacCallum Cancer Centre, Australia | 2021-09-23 |
| Hepatocellular Carcinoma Imaging Using PSMA PET/CT (NCT05095519) | Peter MacCallum Cancer Centre, Australia | 2021-09-08 |
| A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (NCT04914741) | Peter MacCallum Cancer Centre, Australia | 2021-06-29 |
| The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders. (NCT04819607) | Peter MacCallum Cancer Centre, Australia | 2021-06-09 |
| ProsTIC Registry of Men Treated With PSMA Theranostics (NCT04769817) | Peter MacCallum Cancer Centre, Australia | 2021-05-19 |
| Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (NCT04739670) | Peter MacCallum Cancer Centre, Australia | 2021-03-01 |
| COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; (NCT04534725) | Peter MacCallum Cancer Centre, Australia | 2020-12-17 |
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy (NCT04430192) | Peter MacCallum Cancer Centre, Australia | 2020-08-06 |
| Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial (NCT04316013) | Peter MacCallum Cancer Centre, Australia | 2020-07-31 |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (NCT04720768) | Peter MacCallum Cancer Centre, Australia | 2020-06-04 |
| In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (NCT04343885) | Peter MacCallum Cancer Centre, Australia | 2020-04-21 |
| Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma (NCT04234061) | Peter MacCallum Cancer Centre, Australia | 2020-04-07 |
| Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (NCT03900884) | Peter MacCallum Cancer Centre, Australia | 2019-09-25 |
| Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma (NCT03980171) | Peter MacCallum Cancer Centre, Australia | 2019-08-19 |
| PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (NCT03658447) | Peter MacCallum Cancer Centre, Australia | 2019-07-12 |
| 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (NCT03874884) | Peter MacCallum Cancer Centre, Australia | 2019-07-09 |
| A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (NCT03331731) | Peter MacCallum Cancer Centre, Australia | 2018-11-29 |
| Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma (NCT03302728) | Peter MacCallum Cancer Centre, Australia | 2018-08-30 |
| MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (NCT03287427) | Peter MacCallum Cancer Centre, Australia | 2018-08-22 |
| Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer (NCT03464942) | Peter MacCallum Cancer Centre, Australia | 2018-08-01 |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC (NCT03363867) | Peter MacCallum Cancer Centre, Australia | 2018-07-10 |
| High Intensity Functional Image Guided Vmat Lung Evasion (NCT03569072) | Peter MacCallum Cancer Centre, Australia | 2018-07-01 |
| PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia (NCT03429387) | Peter MacCallum Cancer Centre, Australia | 2018-01-08 |
| Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (NCT03307759) | Peter MacCallum Cancer Centre, Australia | 2017-12-07 |